不同头颈部肿瘤患者中质子束治疗与容积旋转调强放疗的颞叶坏死风险
该回顾性研究纳入2015年1月后在本院完成放疗的483例头颈部肿瘤患者,比较鼻咽癌与非鼻咽癌组、质子束治疗与容积旋转调强放疗的颞叶坏死累积发生率。鼻咽癌组颞叶坏死频率高于非鼻咽癌组(5.6% vs 0.4%,p<0.01),调整协变量后风险比为13.35(95%CI 1.37-130.61)。质子束治疗与容积旋转调强放疗的颞叶坏死频率相似(4.7% vs 6.3%,p=0.76)。
要点
- 鼻咽癌患者放疗后早期颞叶坏死频率高于非鼻咽癌患者(5.6% vs 0.4%,p<0.01)。
- 调整协变量后鼻咽癌组颞叶坏死风险显著高于非鼻咽癌组(调整HR 13.35,95%CI 1.37-130.61)。
- 质子束治疗与容积旋转调强放疗的颞叶坏死频率相似(4.7% vs 6.3%,p=0.76)。
核心结论
- 鼻咽癌患者在放疗后早期易发生颞叶坏死。
- 质子束治疗与容积旋转调强放疗相比,在鼻咽癌或其他头颈部肿瘤患者中可能具有相当的颞叶坏死风险。
研究设计与样本
- 回顾性研究,纳入2015年1月后在本院完成放疗的483例头颈部肿瘤患者,随访期间定期行增强磁共振成像或计算机断层扫描,按常见不良事件评价标准第5.0版分级记录颞叶坏死。
主要发现
- 鼻咽癌组与非鼻咽癌组相比,颞叶坏死频率为5.6% vs 0.4%(p<0.01)。
- Kaplan-Meier分析显示鼻咽癌组颞叶坏死累积发生率高于非鼻咽癌组(p<0.01)。
- Cox回归模型调整协变量后,鼻咽癌组颞叶坏死的调整风险比为13.35(95%CI 1.37-130.61)。
- 质子束治疗与容积旋转调强放疗的颞叶坏死频率为4.7% vs 6.3%(p=0.76)。
- Kaplan-Meier分析显示质子束治疗与容积旋转调强放疗的颞叶坏死累积风险在全部头颈部肿瘤(p=0.44)、鼻咽癌(p=0.84)和非鼻咽癌头颈部肿瘤(p=0.70)患者中均相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the frequency of temporal lobe necrosis (TLN) soon after radiotherapy (RT) and identify differences among patients with various types of head and neck cancer (HNC) and between different RT methods. METHODS: We retrospectively reviewed 483 patients with HNC who had completed RT in our hospital after January, 2015. These patients were followed-up at the radio-oncology department and received contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) to identify metastases or recurrence of cancer at regular intervals. Meanwhile, the occurrence of TLN, graded according to the Common Terminology Criteria for Adverse Events V5.0, was recorded. We categorized the patients into nasopharyngeal carcinoma (NPC) and non-NPC groups and compared the cumulative occurrence of TLN between the groups using Kaplan-Meier and Cox regression analyses. We further compared the cumulative occurrence of TLN between proton beam therapy (PBT) and volumetric modulated arc therapy (VMAT) in patients with any HNC, NPC, and non-NPC HNC. RESULTS: Compared with the non-NPC group, the NPC group had a higher frequency of TLN (5.6% vs. 0.4%, p < 0.01) and were more commonly associated with TLN in the Kaplan-Meier analysis (p < 0.01) and the Cox regression model after covariates were adjusted for (adjusted hazard ratio: 13.35, 95% confidence interval: 1.37-130.61) during the follow-up period. Furthermore, the frequency of TLN was similar between patients receiving PBT and those receiving VMAT (PBT vs. VMAT: 4.7% vs. 6.3%, p = 0.76). Kaplan-Meier analysis revealed that the accumulated risks of TLN were similar between PBT and VMAT in patients with any HNC (p = 0.44), NPC (p = 0.84), and non-NPC HNC (p = 0.70). CONCLUSION: Our study demonstrated that patients with NPC are susceptible to TLN during the early period after RT. In addition, PBT may be associated with an equivalent risk of TLN when compared with VMAT in patients with NPC or other HNCs.
引用
- Liu CH, Lin CY, Huang BS, et al. Risk of temporal lobe necrosis between proton beam and volumetric modulated arc therapies in patients with different head and neck cancers. Radiat Oncol. 2023. PMID: 37735389. doi:10.1186/s13014-023-02344-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。